Public Market Listing
Live quotes, historical charts, and market capitalization for Chong Kun Dang Pharmaceutical are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(9 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | GABA-A receptorSmall molecule | Epilepsy | |
| Phase 3 | VEGF-AMonoclonal antibody | Age-Related Macular Degeneration | |
Lobeglitazone(Duvie) | Phase 3 | PPAR-gammaSmall molecule | Type 2 Diabetes |
| Phase 3 | Adenosine A3 receptor | MASH / NASHHepatocellular Carcinoma | |
CKD-506No recent activity | Phase 2 | HDAC6 (Histone deacetylase 6)Small molecule | Rheumatoid Arthritis |
| Phase 1/2 | METAntibody–drug conjugate | Non-Small Cell Lung Cancer | |
Carvedilol (CKD-385)No recent activity | Phase 1 | Beta-adrenergic receptors (nonselective) and alpha-1 adrenergic receptor (antagonist)Small molecule | Hypertension |
| Phase 1 | IL-4R-alphaMonoclonal antibody | Atopic Dermatitis | |
tofacitinib (Chong Kun Dang)No recent activity | Phase 1 | JAK1 / JAK3Small molecule | Rheumatoid Arthritis |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent